Levothyroxine/Liothyronine Combination Therapy and Quality of Life: Is It All about Weight Loss?
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Objectives: According to one hypothesis, the popularity of levothyroxine (L-T 4)/liothyronine (L-T 3) combination therapy relates to weight loss. The purpose of this study was to detect a possible correlation between thyroid-related quality of life (QoL) and weight loss in hypothyroid patients switched from L-T 4 monotherapy to L-T 4/L-T 3 combination therapy. Methods: In an open-label cohort study, all hypothyroid patients referred to the University Hospital endocrine clinic due to persistent symptoms despite adequate L-T 4 monotherapy (without other explanations for the symptoms) were switched from L-T 4 monotherapy to L-T 4/ L-T 3 combination therapy at a ratio of approximately 17/1. At baseline and after 3 months of treatment we measured: QoL by the Thyroid Patient-Reported Outcome (ThyPRO-39) questionnaire, thyroid hormones, body weight, body composition by a DEXA-scan, and cognitive function by evaluating participants’ reaction time as well as working memory by the California Computerized Assessment Package (CalCAP®). QoL was re-evaluated after 12 months. Results: Twenty-three patients participated (91% women, median age 47 years). The ThyPRO-39 composite score decreased from a median of 54 (quartiles: 34, 74) to 15 (11, 28) after 3 months (p < 0.0001), and 20 (14, 26) after 12 months, indicating a better QoL. There was no change in body weight, and no correlations between QoL and weight. There was a slight improvement in cognitive function, whereas body composition, heart rate, and serum TSH did not change. Conclusion: Our study on hypothyroid patients switched from L-T 4 monotherapy to L-T 4/L-T 3 combination therapy showed a substantial improvement in QoL measured by the ThyPRO-39. This improvement could not be explained by weight loss.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, this study was an unblinded study without a control group.”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [103]
In the citing paper
“The 3-month improvement in QoL was not accompanied by a decrease in body weight.”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [103]
In the citing paper
“With initiation of combination therapy, with the LT3 administered twice daily, there was an improvement in both tiredness and cognitive complaints after both 3 and 12 months of treatment (103).”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [103]
In the citing paper
“Anxiety and depression appeared to show little change in response to combination LT4/LT3 treatment, whereas “emotional susceptibility” showed a large change (103).”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [103]
In the citing paper
“The ThyPRO has good cross-cultural validity; the shortened ThyPRO-39, which is now available in many languages, might be preferred [41,85].”
From T4+T3 Combination Therapy: An Unsolved Problem of Increasing Magnitude and Complexity (2021) · cites this paper as [41]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Beecher, H. K. (1955) · Journal of the American Medical Association · doi:10.1001/jama.1955.02960340022006 · Cited by 1,842
2012 ETA Guidelines: The Use of L-T4 + L-T3 in the Treatment of Hypothyroidism
Wiersinga, W. M., Duntas, L., Fadeyev, V., Nygaard, B., & Vanderpump, M. P. J. (2012) · European Thyroid Journal · doi:10.1159/000339444 · Cited by 437
Self-citationPanicker, V., Saravanan, P., Vaidya, B., Evans, J., Hattersley, A. T., Frayling, T. M., & Dayan, C. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1301 · Cited by 327
Taylor, P. N., Iqbal, A., Minassian, C., Sayers, A., Draman, M. S., Greenwood, R., Hamilton, W., Okosieme, O., Panicker, V., Thomas, S. L., et al. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.11312 · Cited by 300
Validity and reliability of the novel thyroid-specific quality of life questionnaire, ThyPRO
Watt, T., Hegedüs, L., Groenvold, M., Bjorner, J. B., Rasmussen, Å. K., Bonnema, S. J., & Feldt-Rasmussen, U. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-0521 · Cited by 210
Self-citationAppelhof, B. C., Fliers, E., Wekking, E. M., Schene, A. H., Huyser, J., Tijssen, J. G. P., Endert, E., van Weert, H. C. P. M., & Wiersinga, W. M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2111 · Cited by 183
Nygaard, B., Jensen, E. W., Kvetny, J., Jarløv, A., & Faber, J. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0542 · Cited by 153
Self-citationWatt, T., Cramon, P., Hegedüs, L., Bjorner, J. B., Bonnema, S. J., Rasmussen, Å. K., Feldt-Rasmussen, U., & Groenvold, M. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1322 · Cited by 152
Self-citationWinther, K. H., Cramon, P., Watt, T., Bjorner, J. B., Ekholm, O., Feldt-Rasmussen, U., Groenvold, M., Rasmussen, Å. K., Hegedüs, L., & Bonnema, S. J. (2016) · PLOS ONE · doi:10.1371/journal.pone.0156925 · Cited by 152
Self-citationDevelopment of a Short Version of the Thyroid-Related Patient-Reported Outcome ThyPRO
Watt, T., Bjorner, J. B., Groenvold, M., Cramon, P., Winther, K. H., Hegedüs, L., Bonnema, S. J., Rasmussen, Å. K., Ware, J. E., & Feldt-Rasmussen, U. (2015) · Thyroid · doi:10.1089/thy.2015.0209 · Cited by 132
Self-citation
Cited by
Jonklaas, J., Bianco, A. C., Cappola, A. R., Celi, F. S., Fliers, E., Heuer, H., McAninch, E. A., Moeller, L. C., Nygaard, B., Sawka, A. M., et al. (2021) · Thyroid® · doi:10.1089/thy.2020.0720 · Cited by 172
“With initiation of combination therapy, with the LT3 administered twice daily, there was an improvement in both tiredness and cognitive complaints after both 3 and 12 months of treatment (103).”
Self-citationPrimary hypothyroidism and quality of life
Hegedüs, L., Bianco, A. C., Jonklaas, J., Pearce, S. H., Weetman, A. P., & Perros, P. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00625-8 · Cited by 144
Optimal thyroid hormone replacement
Jonklaas, J. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab031 · Cited by 89
Jonklaas, J., Bianco, A. C., Cappola, A. R., Celi, F. S., Fliers, E., Heuer, H., McAninch, E. A., Moeller, L. C., Nygaard, B., Sawka, A. M., et al. (2021) · European Thyroid Journal · doi:10.1159/000512970 · Cited by 78
Self-citationT4 + T3 combination therapy: any progress?
Wiersinga, W. M. (2019) · Endocrine · doi:10.1007/s12020-019-02052-2 · Cited by 35
Metadata
- Authors
- Michaelsson, L. F., la Cour, J. L., Medici, B. B., Watt, T., Faber, J., & Nygaard, B.
- Affiliations
- University of Copenhagen (DK)
- 1Department of Endocrinology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark
- Venue
- European Thyroid Journal
- Publisher
- Bioscientifica
- Published
- 2018-07-13
- Volume
- 7
- Issue
- 5
- Pages
- 243-250
- ISSN
- 2235-0640 (ISSN-L)
- 2235-0802
- PMC
- PMC6198786
- OpenAlex
- W2883142002
- Cited by
- 30
- References
- 18
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 4 · 2023: 1 · 2022: 6 · 2021: 5 · 2020: 4 · 2019: 4
- FWCI
- 2.59
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- European Thyroid Journal (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Keywords
- levothyroxine, liothyronine, combination thyroid hormone therapy, hypothyroidism, quality of life, weight loss, cognitive function, body composition, thyroid-stimulating hormone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Levothyroxine/Liothyronine Combination Therapy and Quality of Life: Is It All about Weight Loss? https://app.cochat.ai/papers/10.1159/000490383
- The paper
- Michaelsson, L. F., la Cour, J. L., Medici, B. B., Watt, T., Faber, J., & Nygaard, B. (2018). Levothyroxine/Liothyronine Combination Therapy and Quality of Life: Is It All about Weight Loss? European Thyroid Journal. https://doi.org/10.1159/000490383
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.